The CPAP supply story has been ongoing since the major device recalls and supply chain disruptions of the early 2020s. Several years on, the situation has stabilised substantially but specific constraints remain that affect Australian patients and clinicians. This is a current view of what’s available, what’s harder to source, and what to plan for as we head into the cooler months when CPAP adherence issues often surface.

The most important message is that the broader supply situation is much better than it was. The peak shortage period is well behind us. New device availability across the major brands is largely back to normal trading patterns. What’s left are specific niches where supply remains tight and certain product categories that haven’t fully recovered.

What’s Generally Available

The main CPAP and bilevel device categories from the major manufacturers — ResMed, Philips Respironics (now under their restructured operations), Fisher & Paykel, and others — are generally in adequate supply across the Australian market. New patient setups are happening within reasonable timeframes. Equipment refresh cycles are operating normally.

Most mask categories — nasal, full face, pillows — are available across multiple brands at reasonable replacement intervals. The standard consumables — tubing, filters, headgear — are similarly back in routine supply.

The waiting times that characterised the worst of the supply disruption period have largely resolved. Patients can expect to receive new equipment within reasonable timeframes through normal supply channels.

Where Specific Constraints Remain

A few specific areas where supply remains less straightforward:

Replacement parts for older devices that are no longer in active production. As the affected device cohorts age, the parts supply situation has shifted from peak constraint to longer-tail constraint. Patients with older devices needing repair sometimes face longer turnarounds for specific components.

Some specialised mask configurations remain harder to source than standard variants. Patients with non-standard fit requirements may face more limited choices than they had before the disruption period.

Certain humidifier components and accessories have shown sporadic availability issues, varying by region and supplier.

Specific bilevel device configurations for less common clinical indications have shown intermittent supply tightness.

The pattern is that mainstream high-volume supply is now reliable, while niche or specialised needs sometimes require more lead time and supplier engagement.

The Affected Device Population

The cohort of patients who were affected by the major device recalls is now largely resolved through replacement, repair, or alternative arrangements. The clinical follow-up programs from the affected manufacturers have continued, with most directly affected patients now in stable arrangements with replacement equipment.

The longer-term clinical follow-up to assess any health impacts from the recall situation continues. The findings to date have generally been more reassuring than the worst-case concerns of the recall period suggested, though continued surveillance is appropriate given the scale and duration of the original exposure.

Pricing Has Stabilised

CPAP equipment and supply pricing went through significant disruption during the supply constraint period. The current pricing environment is more stable than it has been for several years, with normal competitive dynamics largely restored.

Patients should expect to see typical pricing for new equipment and supplies through both prescribed clinical channels and the consumer-facing supply channels. The dramatic price variability that characterised the constraint period has largely faded.

The Australian private health insurance arrangements for CPAP coverage have largely returned to pre-disruption patterns. Patients with insurance coverage that includes CPAP equipment should generally find their entitlements operating as expected.

Clinical Workflow Has Adjusted

The clinical workflow for CPAP prescription, setup, and follow-up has incorporated some adaptations from the disruption period that have proven worth keeping:

More structured discussion with patients at the time of prescription about expected equipment lifecycle and replacement timing. Clinicians and patients have a better shared understanding of the equipment commitment than was common before.

Better data flow between prescribing clinicians, equipment suppliers, and ongoing monitoring services. The integration of CPAP adherence data into clinical care has improved partly through necessity during the disruption.

More explicit conversations about equipment alternatives where individual patient response to specific devices is suboptimal. The willingness to consider alternative configurations rather than persisting with poorly-tolerated equipment has improved.

These adaptations are positive developments that emerged partly from the operational discipline required during the supply constraint period.

The Adherence Data Continues to Mature

The aggregation of adherence data from connected CPAP devices has continued to mature. The clinical insight available from this data is more sophisticated than it was a few years ago, supporting better individualised management for many patients.

The privacy and data governance frameworks around this data have also matured. Patient consent and control over data sharing is more explicit than it was. The integration between device data and clinical care records is happening through more structured pathways.

The clinical research insights emerging from aggregated adherence data have informed practice recommendations and clinical decision-making. The CPAP field is more data-informed than it was, with measurable benefits for patient outcomes.

What Patients Should Plan For

For patients on existing CPAP therapy in mid-2026, the practical position:

Equipment replacement cycles can proceed through normal supply channels. Plan ahead for the typical lead times your supplier indicates, particularly if you have specific configuration requirements.

Consumable supplies — masks, tubing, filters — should be available through your usual channels. Maintaining a small buffer stock is sensible but the panic buying behaviour from the constraint period is no longer necessary.

For specialised or non-standard equipment needs, engage with your clinician and supplier early. The mainstream supply is fine. Specialised supply may require more planning.

The cooler months ahead often produce CPAP adherence challenges related to humidification, temperature comfort, and seasonal congestion. Engage with your clinical team if you experience adherence difficulties rather than discontinuing therapy.

For New Patients

Patients newly diagnosed with sleep-disordered breathing and being initiated on CPAP therapy in 2026 can generally expect a routine experience. Equipment is available, the trial-and-titration process can proceed normally, and the supply chain disruptions of the past are largely behind the system.

The clinical pathways for sleep study, diagnosis, and treatment initiation have generally returned to pre-disruption operation. Waiting times for sleep studies in the public system remain longer than ideal in some regions, but the private pathway is operating normally.

The patient education about CPAP therapy continues to evolve. The honest framing — that CPAP is the most effective treatment for moderate-to-severe sleep apnoea but requires ongoing commitment to be effective — is now more consistently part of the initial conversation.

The Mid-2026 Position

The CPAP supply situation in Australia in 2026 is fundamentally stable. The dramatic disruptions are behind us. Mainstream supply is reliable. Pricing is stable. Clinical pathways are operating normally for most patients.

What remains true is that CPAP therapy is a long-term clinical commitment that benefits from ongoing attention from both patients and clinicians. The supply infrastructure supporting this commitment is now in reasonable shape after a difficult period. Patients and clinicians who experienced the worst of the disruption can return to more routine clinical management with reasonable confidence in equipment availability.

The lessons from the disruption period — about supply chain resilience, manufacturer relationships, clinical workflow integration — have been substantially incorporated into how the Australian sleep medicine sector operates. The next period of equipment supply turbulence, when it eventually comes, will probably be navigated better than the last one was. For now, the operational position is broadly satisfactory.